91 related articles for article (PubMed ID: 9584045)
1. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.
Viñolas N; Molina R; Galán MC; Casas F; Callejas MA; Filella X; Grau JJ; Ballesta AM; Estape J
Anticancer Res; 1998; 18(1B):631-4. PubMed ID: 9584045
[TBL] [Abstract][Full Text] [Related]
2. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
3. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
Boher JM; Pujol JL; Grenier J; Daurès JP
Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885
[TBL] [Abstract][Full Text] [Related]
4. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
5. [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer].
Fukuoka M; Takada M; Kamei T; Negoro S; Kusunoki Y; Matsui K; Ryu S; Sakai N; Takifuji N; Masuda N
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):871-80. PubMed ID: 3032108
[TBL] [Abstract][Full Text] [Related]
6. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
8. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
[TBL] [Abstract][Full Text] [Related]
9. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
10. Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity?
Zych J; Sakowicz A; Radzikowska E; Załeska J; Rowińska-Zakrzewska E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():173-8. PubMed ID: 9337535
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
[TBL] [Abstract][Full Text] [Related]
12. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
13. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
14. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
15. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
16. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
17. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
Ebert W; Muley T; Trainer C; Dienemann H; Drings P
Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
[TBL] [Abstract][Full Text] [Related]
18. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
Schneider J; Velcovsky HG; Morr H; Katz N; Neu K; Eigenbrodt E
Anticancer Res; 2000; 20(6D):5053-8. PubMed ID: 11326667
[TBL] [Abstract][Full Text] [Related]
20. [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival].
Załeska M; Szturmowicz M; Zych J; Roszkowska-Sliz B; Demkow U; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2010; 78(1):14-20. PubMed ID: 20162514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
